Summer is finally here, bringing with it a well-deserved break for many of you after a year filled with ups, downs, highs, lows and more than a few hurdles to leap.
We hope you’re reflecting proudly on how you’ve navigated these last six months!
As our team at Practice Business prepares to wind down for the summer break, we’ll be pausing our website and news email service for a couple of weeks. However, behind the scenes, we’ll be hard at work refreshing our digital content. We’re gearing up to return with exciting news and features that will kick off the next chapter of 2024 with energy and enthusiasm.
We’re here throughout the summer and always eager to connect, so feel free to reach out via email if you have any questions or just want to say hello!
Wishing you all a wonderful summer — see you on the other side!
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment